Welcome to our dedicated page for Neurocrine Biosciences news (Ticker: NBIX), a resource for investors and traders seeking the latest updates and insights on Neurocrine Biosciences stock.
Neurocrine Biosciences Inc. reports biopharmaceutical developments across neurological, psychiatric, endocrine and immunological disorders. Recurring updates include commercial and clinical information for INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease, CRENESSITY for classic congenital adrenal hyperplasia, and approved therapies for endometriosis and uterine fibroids.
Company news also covers CAHtalyst clinical data, peer-reviewed publications on glucocorticoid dosing and the Tardive Dyskinesia Impact Scale, pipeline programs such as NBIP-'2118, financial results, healthcare conference participation, and governance or capital-structure matters tied to Neurocrine's public-company reporting.
Neurocrine Biosciences (Nasdaq: NBIX) has completed patient enrollment for the Phase 3 KINECT-HD study, investigating the efficacy and safety of valbenazine for treating chorea in Huntington disease. The top-line results are expected by the end of 2021. This study offers hope for the approximately 30,000 U.S. adults affected by Huntington disease, whose current treatment options carry significant risks. Following KINECT-HD, participants can join KINECT-HD2, an open-label extension study to evaluate long-term safety.
Neurocrine Biosciences (NBIX) reported Q2 2021 financial results, with total revenues of $288.9 million, down from $302.4 million in Q2 2020. Product sales for INGREZZA were $266.8 million, a slight decline from $267.6 million year-over-year. GAAP net income fell to $42.3 million ($0.43 per share) compared to $79.6 million ($0.81 per share) in Q2 2020. Increased R&D and SG&A expenses significantly impacted earnings. Notably, the company is advancing its R&D pipeline with plans for nine mid-to-late-stage trials in 2021.
Neurocrine Biosciences (Nasdaq: NBIX) will announce its second quarter 2021 financial results on August 3, 2021, after Nasdaq market closure. A conference call and webcast will follow at 1:30 p.m. PT to discuss the results and company updates. Participants can join the call by dialing 866-952-8559 (US) or 785-424-1743 (International) using conference ID: NBIX. The webcast will be available on the Neurocrine website and archived for one month.
Neurocrine Biosciences (Nasdaq: NBIX) announced its participation in the William Blair Biotech Focus Conference on July 15, 2021, where Kyle Gano, Chief Business Development and Strategy Officer, will take part in a panel discussion focused on neuropsychology. The live presentation is scheduled for 12:00 p.m. Eastern Time and will be webcast via the company's website. A replay will be available shortly after the event and archived for one month. Neurocrine specializes in developing treatments for neurological and psychiatric disorders.
Neurocrine Biosciences (Nasdaq: NBIX) will present at the Goldman Sachs 42nd Annual Global Healthcare Conference on June 8, 2021, at 1:20 p.m. ET. CEO Kevin Gorman will lead the presentation. Attendees can access the live webcast on the company's website, with a replay available about an hour after the event, archived for one month. Neurocrine focuses on developing treatments for neurological and endocrine disorders, with a portfolio that includes FDA-approved therapies for tardive dyskinesia, Parkinson's disease, and more.
Neurocrine Biosciences (Nasdaq: NBIX) will present at the 2021 RBC Capital Markets Healthcare Conference on May 18, 2021 at 10:55 a.m. Eastern Time. The presentation will feature CFO Matt Abernethy and CMO Eiry Roberts. Interested parties can access the live webcast on the company's website, with a replay available afterward for one month. Neurocrine focuses on innovative treatments for neurological and psychiatric disorders, with a portfolio that includes FDA-approved therapies for tardive dyskinesia and Parkinson's disease.
Neurocrine Biosciences (NBIX) reported $236.6 million in total revenues for Q1 2021, slightly down from $237.1 million in Q1 2020. Product sales from INGREZZA were $231 million. GAAP net income decreased to $32.1 million, with diluted earnings per share at $0.33 compared to $0.39 in the previous year. The company revised its full-year expense guidance to $855-$905 million for GAAP R&D and SG&A. Despite lower refill rates attributed to seasonal payor dynamics and COVID disruptions, new patient starts for INGREZZA improved late in the quarter, signaling a potential recovery.
Neurocrine Biosciences (Nasdaq: NBIX) will present at the Bank of America 2021 Healthcare Conference on May 11, 2021, at 11:00 a.m. Eastern Time. CEO Kevin Gorman will lead the presentation, which will be webcast live on the company's website. A replay will be available shortly after the event and archived for a month. Neurocrine focuses on developing treatments for neurological, endocrine, and psychiatric disorders, offering FDA-approved therapies for conditions like tardive dyskinesia and Parkinson's disease.
Neurocrine Biosciences (Nasdaq: NBIX) announced the appointment of Johanna Mercier to its Board of Directors. Mercier, currently the Chief Commercial Officer at Gilead Sciences, brings extensive experience from her 25-year tenure at Bristol Myers Squibb, where she led successful commercial strategies, particularly in oncology. Her expertise is anticipated to enhance the company's direction in developing treatments for neurological and endocrine disorders. The announcement underscores the company's commitment to strengthening its leadership team.
Neurocrine Biosciences (Nasdaq: NBIX) will release its first quarter 2021 financial results after market close on May 5, 2021. A conference call and webcast to discuss the results will follow at 1:30 p.m. PT (4:30 p.m. ET). Participants can join via phone or by accessing the webcast on the company’s website. Neurocrine focuses on developing treatments for neurological, endocrine, and psychiatric disorders, with a portfolio that includes FDA-approved therapies for conditions such as tardive dyskinesia and Parkinson's disease.